English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M SCCHN) have a poor prognosis with a median survival of 6 to 10 months1. Selected patients with locally recurrent disease can be treated with a curative intent with locoregional therapies, such as salvage surgery and/or radiotherapy; however, the vast majority of patients die from their disease. Chemotherapy remains the cornerstone of treatment this setting2.

Palliative Chemotherapy in Recurrent or Metastatic Squamous cell carcinoma of the head and neck, NEMROCK experience